Latest News
Elligo Health Research Acquires Protenium Clinical Research
Friday 11 January 2019

11 January 2019 - US-based integrated research organisation Elligo Health Research has acquired Protenium Clinical Research, the company said.

Protenium, an established research group led by Robert Strzinek, Ph.D., D.O., conducts pharmaceutical studies in a broad range of therapeutic areas.

Strzinek has more than 15 years of clinical research experience and will now conduct research at his practice in partnership with Elligo.

The acquisition brings the number of patients in Elligo's Research Ready network to more than 1m.

As part of Elligo's Goes Direct approach, these patients will now have access to clinical research as a care option from their own trusted physician.

Strzinek has completed over 150 research studies and authored numerous journal articles covering several areas including endocrinology and women's health.

He and the Elligo team will continue to conduct research and support other community-based health care providers participating in research.

Elligo Health Research, an integrated research organisation, expands access to clinical research by bringing together health care data, community physicians and their patients.
Date Published: 11/01/2019
Target: Protenium Clinical Research
Country: USA
Sector: Healthcare
Type: Corporate acquisition
Status: Closed
Buyer: Elligo Health Research
Terms of the deal were not disclosed